Literature DB >> 8395770

Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin.

O Inbar1, M Blank, D Faden, A Tincani, M Lorber, Y Shoenfeld.   

Abstract

OBJECTIVE: The purpose of this study was to compare the effectiveness of low-molecular-weight heparin with regular heparin in the prevention of fetal resorption in mice with the antiphospholipid syndrome. STUDY
DESIGN: Antiphospholipid syndrome was passively induced in ICR mice by injecting them with anticardiolipin antibodies on the first day of pregnancy. Subsequently, these mice were treated with low-molecular-weight heparin in two different doses, with regular heparin, and with a placebo. On gestational day 17 the mice were killed by cervical dislocation, and the pregnancy outcome was evaluated. Statistical analysis was performed by means of a one-way analysis of variance using Bonferroni's t test.
RESULTS: Treatment with low-molecular-weight heparin resulted in a resorption rate of 22.4% as opposed to 41.4% in mice with antiphospholipid syndrome that were given regular heparin and 51.7% in nontreated controls.
CONCLUSION: We conclude that low-molecular-weight heparin can prevent fetal resorptions in mice with antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395770     DOI: 10.1016/0002-9378(93)90100-w

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  4 in total

Review 1.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 2.  Lupus pregnancies and neonatal lupus.

Authors:  M D Lockshin
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.

Authors:  I Krause; M Blank; Y Levi; T Koike; V Barak; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

4.  Recurrent fetal loss and antiphospholipid antibodies: clinical and therapeutic aspects.

Authors:  O Blétry; A M Piette
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.